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Abstract
Avian inﬂuenza A(H9N2) viruses are an increasing threat to global poultry production and, through zoonotic infection,
to human health where they are considered viruses with pandemic potential. Vaccination of poultry is a key element
of disease control in endemic countries, but vaccine effectiveness is persistently challenged by the emergence of
antigenic variants. Here we employed a combination of techniques to investigate the genetic basis of H9N2 antigenic
variability and evaluate the role of different molecular mechanisms of immune escape. We systematically tested the
inﬂuence of published H9N2 monoclonal antibody escape mutants on chicken antisera binding, determining that
many have no signiﬁcant effect. Substitutions introducing additional glycosylation sites were a notable exception,
though these are relatively rare among circulating viruses. To identify substitutions responsible for antigenic variation
in circulating viruses, we performed an integrated meta-analysis of all published H9 haemagglutinin sequences and
antigenic data. We validated this statistical analysis experimentally and allocated several new residues to H9N2
antigenic sites, providing molecular markers that will help explain vaccine breakdown in the ﬁeld and inform vaccine
selection decisions. We ﬁnd evidence for the importance of alternative mechanisms of immune escape, beyond simple
modulation of epitope structure, with substitutions increasing glycosylation or receptor-binding avidity, exhibiting the
largest impacts on chicken antisera binding. Of these, meta-analysis indicates avidity regulation to be more relevant to
the evolution of circulating viruses, suggesting that a speciﬁc focus on avidity regulation is required to fully understand
the molecular basis of immune escape by inﬂuenza, and potentially other viruses.
Introduction
In recent years, novel avian inﬂuenza virus (AIV) strains
have emerged as a major threat to animal and human
health. H9N2 AIVs are endemic across much of Asia, the
Middle East and North Africa, where they cause severe
economic losses to the poultry industry through
moderate-to-high morbidity and mortality1–3. H9N2
viruses are an emerging threat to poultry in new geo-
graphic regions, with the ﬁrst reported sequences found in
Russia, Sub-Saharan Africa and Indonesia occurring
within the last year4–7. In addition, certain H9N2 lineages
are considered to have pandemic potential owing to their
repeated isolation from humans and their ability to adapt
to and transmit between ferrets, the animal model for
human transmission8–10. Certain H9N2 virus internal
gene constellations have a unique capacity to elevate the
zoonotic potential of non-H9N2 AIVs with recent
examples including H7N9, H10N8 and clade 2.3.4.4
H5N6, all known to have high mortality rates in
humans11.
Owing to the threat to poultry and human health posed
by endemic and emerging H9N2 AIVs, many countries
vaccinate poultry as a major method of viral control, with
conventional inactivated vaccines being used most com-
monly12–14. However, as with human inﬂuenza virus, poor
vaccine matching owing to antigenic drift often results in
vaccine failure3,12,14,15. Immunity, following infection or
vaccination, is primarily achieved by the generation of
neutralising antibodies that interact with haemagglutinin
(HA), the major inﬂuenza antigen and receptor-binding
protein, sterically blocking attachment to target cells16.
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Consequently, the antigenic variability of inﬂuenza viru-
ses, commonly assessed using the haemagglutination
inhibition (HI) assay, can largely be mapped to amino-
acid substitutions near the HA receptor-binding site17,18.
These substitutions have been found to contribute to both
actual and apparent antigenic change via a variety of
mechanisms, namely changes to epitope structure,
acquisition of additional glycosylation sites and modula-
tion of receptor-binding avidity19–21.
Amino-acid substitutions that alter the biophysical
properties (shape, charge, polarity, etc.) of an epitope have
the potential to cause antigenic change by directly
affecting antibody binding. This is the most conventional
mechanism of immune escape. The acquisition of addi-
tional N-linked glycosylation sites is another mechanism
by which inﬂuenza viruses may escape antibody neu-
tralisation;20,21 bulky oligosaccharides can sterically
‘shield’ HA epitopes from antibody recognition and the
antibody response is potentially directed to alternative
antigenic sites22. In the absence of compensatory muta-
tions, additional glycosylation has been described to
reduce receptor-binding avidity, which has been hypo-
thesised to restrict hyper-glycosylation as an immune
evasion strategy21,23. Neutralising antibodies competi-
tively inhibit HA receptor interactions. Amino-acid sub-
stitutions that modulate receptor-binding avidity can
therefore contribute to apparent antigenic change detec-
ted by HI assays. Modulation of avidity has been hypo-
thesised to be a true form of immune escape, rather than
an artefact of the HI assay19,24. The relative roles of each
of these mechanisms in evolution across inﬂuenza sub-
types and the consequences for vaccine effectiveness is
not well known.
Previously, we used a ‘classical’ monoclonal antibody
(mAb) escape mutant approach to investigate the anti-
genic architecture of the H9 HA, identifying several
residues that were assigned to two discrete antigenic sites,
‘H9-A’ and ‘H9-B’25. Although these residues were
important for the binding of murine mAbs, their sig-
niﬁcance in the context of circulating ﬁeld viruses
remained unknown. Many residues identiﬁed in our
previous study, as well as several similar published stu-
dies26–30, are completely conserved among circulating
viruses, indicating they are not responsible for antigenic
variability observed in the ﬁeld.
In this paper, we identify amino-acid residues and
substitutions responsible for H9N2 virus antigenic varia-
bility in the ﬁeld through a variety of approaches. We
reconstitute mutations at every published H9 HA
monoclonal escape mutant position25–30 and test the
effect of these substitutions on polyclonal chicken antisera
binding. We then adapt an approach previously developed
for human inﬂuenza viruses17, performing a meta-analysis
of all published H9 HI assay and corresponding genetic
data to identify naturally occurring antigenically impor-
tant substitutions. We identify substitutions that correlate
with antigenic changes and prove causation using reverse
genetics and HI assays. Several novel antigenic residues
are predicted, which we demonstrate are indeed relevant
to the antigenic diversity of ﬁeld H9N2 viruses. Overall,
we provide a comprehensive and systematic analysis of
the molecular basis of H9 HA antigenic diversity in
chickens, which are routinely vaccinated by the poultry
industry and hence the critical host species for under-
standing risks of vaccine escape.
Results
Antigenic impact of escape mutant viruses
Six studies describe a total of 39 unique mAb escape
mutations in H9N2 HA1 across 30 amino-acid posi-
tions25–30 (Table S1). Viruses were generated with
mutations at each published escape residue in the HA of
the H9N2 virus A/chicken/Pakistan/UDL-01/2008
(UDL1/08) and tested using HI, with a panel of eight anti-
UDL1/08 chicken post infection antisera, to assess the
impact of these mutations on antigenicity. When multiple
escape mutants were reported at the same position, the
mutation or mutations, which introduced the largest dif-
ference in biophysical properties were generated (e.g., of
T129K and T129A, only T129K was tested). Furthermore,
alternative, more biologically relevant mutations at escape
sites were introduced in some cases (64% of published
escape mutations are absent or almost absent (frequency
< 1%) amongst sequenced H9N2 viruses, Table S2).
Mutants unable to be rescued in the UDL1/08 back-
ground were dropped from further study (Table S3).
In total, 44 mutants at 30 positions described in escape
mutant studies were assessed by HI assay (Fig. 1). Of
these, 25 at 20 positions showed signiﬁcant reductions in
HI titre compared with wild-type UDL1/08. Several of the
introduced substitutions—19 at 16 amino-acid positions
—caused no signiﬁcant change in titre. Interestingly, of
the seven substitutions with the largest impact on chicken
antiserum binding ( ≥ 1.30 log2 titre), four corresponded
to the addition of glycosylation sites (T127N, L150S,
T188N and D189N), while the remaining three corre-
sponded to known receptor-binding residues (T145I,
L216Q and I217Q)9,31–33. Each of these four glycosylation
mutants were tested for the presence of the additional
glycans by western blot and all displayed upward band
shifts, consistent with the addition of glycosylation sites
(Fig. S1). Complete N-linked glycan motifs at the sites of
the four glycosylation site mutants tested are, however,
rare among sequenced ﬁeld isolates (Table 1).
Of the tested mutations found to signiﬁcantly affect
chicken antiserum binding, several are unable to con-
tribute signiﬁcantly to antigenic variability among circu-
lating strains owing to their rareness in nature. For
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example, positions 115, 129, 145 and 189 (as well as non-
signiﬁcant positions 98, 137, 147, 152, 212 and 234) are all
> 98% conserved (Table S2). For a sample of viruses
covering all major H9N2 lineages, amino-acid identity at
each of the 20 escape mutant sites where a signiﬁcant
impact on HI titre was detected is shown in Fig. 2
(an expanded ﬁgure including all 30 escape mutant sites is
shown in Fig. S2A). Of the 39 published escape mutations,
27 (69%) had no signiﬁcant impact on HI titres, were
absent or almost absent among sequenced viruses, or both
(Fig. 1). At 10 of the 30 published escape sites, no evi-
dence of an antigenic impact in HI assays was detected,
even when taking alternative substitutions at the site into
account. These results suggest that antibodies in chicken
polyclonal antisera do not consistently recognise the same
epitopes as mouse mAbs or that there are differences in
immunodominance, and that further sites likely con-
tribute to antigenic variation of H9N2 viruses in nature.
Modelling of HI and genetic data and prediction of
antigenically pertinent substitutions
To investigate genetic differences responsible for H9N2
ﬁeld strain antigenic diversity, we performed an integrated
statistical analysis of antigenic and genetic data. All pub-
lished HI data for H9N2 with associated HA1-nucleotide
sequences were compiled (citations in Table S4) and
supplemented with additional HI assays (Table S5). The
assembled data set comprised 330 H9N2 virus sequences
covering all major lineages (Fig. 2), including 103 viruses
against which antisera were raised, with a total of 2574
individual HI titres measured between 2131 unique
combinations of virus and antiserum.
Linear mixed models were used to account for variation
in HI in terms of viral sequence changes, as previously
described17. Initial model selection determined variables
representing systematic differences in the magnitudes of
titres recorded for individual test viruses, for antisera
raised against particular reference viruses, for different
serum types (i.e, live virus vs inactivated vaccination, and
chicken vs ferret), and for different studies. To control for
repeated measures that arise from phylogenetic correla-
tions in the data and prevent false-positive support for
substitutions, branches of the HA1 phylogeny correlated
with drops in HI titre were identiﬁed next, and then terms
representing substitutions at each variable HA1 position
were tested to determine whether their inclusion sig-
niﬁcantly improved model ﬁt.
This analysis identiﬁed antigenically distinct amino
acids at 12 HA1 positions (74, 121, 131, 135, 150, 180,
183, 195, 198, 216, 249 and 288). Of these, seven had been
identiﬁed in published H9N2 mouse mAb escape studies
(74, 131, 135, 150, 183, 188 and 216), including positions
in previously described antigenic sites (Table 2)25,27.
Several additional residues were identiﬁed when ferret or
Fig. 1 Impact of mutation at published mAb escape sites on
haemagglutination inhibition titres performed with polyclonal
chicken antisera. Change in log2 HI titre associated with stated
amino-acid replacements, based on eight individual anti-UDL1/08
antisera with a minimum of ﬁve technical repeats, are indicated by cell
colouring according to the colour legend with non-signiﬁcant
differences shown in grey and untested substitutions in white.
Published mAb escape mutations are shown to the left of centre,
whereas alternative substitutions are shown to the right. Mutations
that introduce absent or almost absent amino-acid states ( < 1% of
sequenced natural isolates) are labelled in smaller, italicised, grey font.
* addition of potential glycosylation site. † would not rescue. ‡ Q146H
rescued with additional substitution T186K
Table 1 Frequency of potentially antigenic glycosylation
sites in natural H9 isolates
Potential glycosylation site
positiona
Mutant(s) in this
studyb
Frequencyc
127–129 S127N, T127N 6.8%
131–133 K131N 0.1%
148–150 A150T, L150S 1.5%
188–190 T188N 2.6%
189–191 D189N 0.1%
aPotential glycosylation sites deﬁned as amino-acid motif N-X-S/T, where X is not
P; bMutants described in Fig. 1, mutants made in this study shown in bold; cTotal
frequency of potential glycosylation site at this position, based on full length
H9 sequences in the NCBI database as of July 2017
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chicken antisera data sets were analysed independently
and were also considered (72, 217, 264, 276 and 306), a
further two (72 and 217) had also been described by
escape mutant studies25,26. Among the speciﬁc substitu-
tions inferred to be antigenically relevant, G72E, K131N,
N183T and L216Q are published mAb escape mutations;
G72E, N183T and L216Q (K131N could not be rescued)
were also conﬁrmed to signiﬁcantly reduce binding by
polyclonal chicken antisera in HI assays above (Fig. 1).
Amino-acid identity at each of the 17 HA positions
identiﬁed using this modelling approach is shown for each
virus included in the analysis in Fig. S2B.
Antigenic characterisation of mutant viruses to test
predictions
To validate the predictions of modelling HI and genetic
data, we tested mutant viruses using HI assays and
compared titres with those measured using parental
viruses. Mutant libraries were generated in the
backgrounds of three antigenically distinct H9N2 viruses,
UDL1/08, A/Hong Kong/33982/2009 (HK/33982) and A/
chicken/Emirates/R66/2002 (Em/R66). Wherever possi-
ble, mutations were made that were reciprocal between
these viruses (i.e., UDL1/08 naturally has 183 N and HK/
33982 has 183 T, substitution between N and T at 183 is
predicted to have an antigenic effect therefore UDL1/08
N183T and HK/33982 T183N were generated and tested).
When reciprocal substitutions were introduced, both
mutant viruses were tested using antiserum raised against
both parent viruses. Changes in mean log2 titre relative to
the parent virus, against both parental and mutant-like
antiserum, are detailed in Table S6.
Of the 26 amino-acid substitutions from Table 2
introduced, 19 resulted in signiﬁcantly different titres
measured when using parental antiserum (G72E, E72G,
R74G, I121T, T121I, K131I, D135G, A150L, A180E,
E180A, N183D, N183T, T183N, L216Q, Q216L, I217Q,
Q217I, I249V and V249I), whereas seven did not (K131A,
Fig. 2 Sequence variation at antigenically signiﬁcant H9 haemagglutinin escape mutant sites. Time-resolved Bayesian HA1 phylogeny and
amino-acid identity at each of the 20 mAb escape residues found to signiﬁcantly affect HI titres with polyclonal chicken antisera. Amino-acid identity
is shown by colour, grouped by side-chain property, according to the legend. Each virus (n= 330) included in the phylogeny has associated HI data
and was included in integrated modelling of genetic and antigenic data
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K131S, G135D, L150A, L150F, F150L and D198N). For
substitutions introduced into the UDL1/08 background at
escape mutation sites, effect sizes are shown in Fig. 1 and
where reciprocal forward and reverse mutations were
introduced in different backgrounds, effect sizes are
shown in Fig. 3. In Fig. 3, lower or higher HI titres
recorded for mutant viruses, relative to the parental virus,
are shown in shades of orange and blue, respectively.
Generally, drops in titres were observed against the par-
ental antiserum and increases were observed against
antiserum possessing the introduced substitution, sug-
gesting reduced and increased antibody recognition
respectively (Fig. 3).
Testing mutant viruses using antisera raised both
against the parent virus, and against a virus possessing the
introduced amino-acid state, allowed us to calculate the
relative contributions of antigenic and avidity effects
(Equation 1, Materials and Methods). The impact on HI
titre of altered antigenicity and avidity associated with
each pair of reciprocal substitutions is shown in Fig. 3
(and Table S6). Of the 11 reciprocal pairs considered, two
were estimated to inﬂuence HI titres as a result of altered
antigenicity alone (72 G/E and 183 N/T), four as a result
of altered avidity only (121I/T, 217 L/Q, 217I/Q and 249I/
V) and ﬁve as a combination of these effects (135D/G,
150 A/L, 150 F/L, 180 A/E and 216 L/Q), indicating that
both these mechanisms of immune escape are potentially
playing a role in the evolution of H9N2 viruses.
The impact of substitutions between A and E at position
180 show a classic antigenic signature (Fig. 3). Both
A180E and E180A were associated with signiﬁcant drops
in log2 titre of 0.61 and 0.54 measured using antiserum
raised to the parental virus, UDL1/08 (180A) and Em/R66
(180E), respectively. Both A180E and E180A also
increased titres, by 0.65 and 1.51, respectively, measured
using mutant-like antiserum that possessed the intro-
duced amino acid at position 180. These changes in titre
indicate that the A180E substitution has decreased and
increased the reactivity of antibodies raised against 180 A
and 180E viruses, respectively; a consistent pattern was
observed with the E180A substitution. Consequently, a
sizeable antigenic effect (0.86 log2 titre) is estimated
alongside a smaller avidity effect (± 0.25 log2 titre). Similar
patterns of change in titres indicated sizeable antigenic
effects for substitution between G and E at position 72
and between N and T at 183.
Exchange of Q and L at position 216 represents an
example of a substitution impacting HI titres owing to
altered receptor-binding avidity (Fig. 3). L216Q reduced
titres against antisera both lacking the introduced amino-
acid state, UDL1/08 (216L) and possessing it, Em/R66
(216Q). Conversely, Q216L increased titres against anti-
sera both lacking (Em/R66) and possessing (UDL1/08) the
introduced amino-acid state. These changes indicate that
an H9 HA possessing 216Q has higher avidity than a virus
with 216 L, resulting in lower HI titres generally, regard-
less of whether antiserum was raised to a 216Q or 216 L
virus. We were able to conﬁrm this conclusion in a
receptor destroying enzyme-based avidity assay, where
swapping the single amino acid at position 216 between
UDL1/08 and Em/R66 allowed an almost complete swap
of avidity phenotypes (Fig. S3). Similar effects of avidity on
HI titres were observed at positions 121, 217 and 249.
Interestingly, L216Q, I217L and I217Q, which each result
in drops in HI titre due to altered avidity (Fig. 3) are either
published mAb escape mutations or occur at the same
position as escape mutations (Fig. 1). This indicates that
increased avidity facilitated by single amino-acid sub-
stitutions is a mechanism of immune escape for H9.
Closer observation of the pattern of change in HI titre at
position 135 suggests an asymmetric antigenic effect of
substitutions between D and G at this position. The
average impacts on titre of either D135G or G135D were
signiﬁcant and large (− 0.90 and + 0.73) when measured
Table 2 Amino acids substitutions correlating with
antigenic change and corresponding antigenic sites
HA positiona Described, or
equivalent
antigenic site
Antigenically distinct amino
acids
H9 H1 H3
72 H9-B Cb E E-G-R
74 UCb Cb E G-R
121 -c I-T
131 UC A K-A/I/R/S, A-R
135 Site II Ca2 A D-G-N, D-E
150 Site I Sb B A/F/N-V/L, F-S-T
180 - Sb B A-E-T, A-V, E-D
183 Site II/H9-
A
Sb B N-D/E/T
195 - A-T
198 - Ca1 D D-N
216 Site II Ca2 D L-Q
217 H9-A D I-Q/T
249 - A/V-I
264 - C K-N
276 - K-R
288 - C I-V
306 - I-K
aH9 mature numbering used throughout; bUC indicates known antigenic residue
(by escape mutant residue) in H9 not previously categorised into a speciﬁc
antigenic site; cdash indicates site not previously described as being antigenic
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with antisera raised against 135D containing UDL1/08. In
contrast, no signiﬁcant impact on titres were observed
using antisera raised against 135 G containing HK/33982,
consistent with 135D belonging to an immunodominant
epitope. A model that estimated two antigenic effects of
substitutions between D and G, depending on which
antiserum was used, rather than a single antigenic effect
was found to improve model ﬁt as assessed by deviance
information criterion34. Experimental studies have pre-
viously demonstrated an asymmetric effect at the homo-
logous HA position in human A(H3N2) viruses24. The
same asymmetric model was also favoured in an analysis
of H3 HI titres associated with the asymmetric effect
reported by Li et al. (2013)24.
Mapping of substitutions into antigenic sites using mAbs
Previously, we described a panel of mouse mAbs against
UDL1/08 binding to two discrete antigenic sites, ‘H9-A’
and ‘H9-B’25. These mAbs were used to perform HI assays
against every mutant virus generated in this study. If a
mutant virus had lower titres to mAbs from either group,
but not the other, the residue was assigned to the corre-
sponding antigenic site. The mutants G149K, T179N,
A180D and A180E reduced titres to H9-A-binding mAbs,
indicating positions 149, 179 and 180 likely form part of
antigenic site H9-A alongside residues 145, 146, 183, 212,
217 and 234. Titres for mutants G72E and D135G indi-
cated these positions form part of site H9-B alongside
residues 115, 120, 139 and 162 (Fig. 4, Table 3 and S7).
The four glycosylation mutants (T127N, L150S, T188N
and D189N) reduced titres to both H9-A and H9-B mAbs
suggesting that the addition of bulky glycans may block
antibody binding to both sites. The substitutions K131I,
D178Y, T182R, L216Q, I217M and I217Q also slightly
reduced binding of mAbs from both groups. These resi-
dues may either lie between antigenic sites and exert an
effect on both, or, these substitutions may overcome
antibody binding by increasing HA receptor-binding
avidity.
Discussion
Determining the molecular mechanisms of antigenic
evolution is vital to understanding viral disease dynamics,
and vaccine selection and development. We have pre-
sented here a systematic analysis of the molecular basis of
H9N2 antigenicity. We assessed the contribution of resi-
dues reported by the literature to be antigenic and their
relation to virus antigenic diversity and showed that
previous studies based on murine mAb escape mutants
are only moderately reliable at providing relevant anti-
genic information; several false positives found to have no
impact on inhibition of chicken antisera were identiﬁed,
as were residues that are very highly conserved in the
ﬁeld. Furthermore, we carried out a meta-analysis of all
available matching genetic and antigenic data for H9N2
viruses, modelling the relationship between genotype and
antigenic phenotype to identify novel residues directly
responsible for observed antigenic diversity in the ﬁeld,
and we categorised these residues into recently deﬁned
antigenic sites. Analysis of reciprocal mutations intro-
duced by reverse genetics allowed us to differentiate
multiple mechanisms facilitating immune escape includ-
ing addition of glycans and increased receptor-binding
avidity, as well as conventional changes to epitope struc-
ture that directly affect antibody binding.
In this study, substitutions with the largest impact of
antigenicity were associated with two distinct mechanisms
of immune evasion. Of the eight most signiﬁcant mutants,
four (T127N, L150S, T188N and D189N) possessed
additional glycosylation sites and four (T145I, L216Q,
I217Q and I249V) possessed substitutions either known
to inﬂuence receptor-binding avidity in H9N2 viruses or
determined to do so in this study through analysis of
reciprocal mutants, or both9,31–33,35. These observations
demonstrate the potential of alternative mechanisms,
other than reduction of antibody recognition by altering
epitope biophysics, in facilitating immune escape and
determining antigenic diversity of H9N2 viruses. Sub-
stitutions altering avidity were well represented among
those identiﬁed by modelling of antigenic and genetic data
collected from H9N2 ﬁeld strains, suggesting that avidity
regulation may be an important mechanism of immune
escape in nature. In contrast, substitutions associated with
acquisition of additional glycans were largely absent,
suggesting this to be a less-important mechanism, possi-
bly owing to an associated ﬁtness cost, as reported else-
where for human inﬂuenza21.
Implementing a systematic approach allows for the
comprehensive evaluation of the phenotypic impact of
amino-acid substitutions. For example, we identify sub-
stitutions at the novel antigenic residue 180 that explain
signiﬁcant antigenic variation among natural viruses
sampled across the H9N2 phylogeny. The analysis of
reciprocal substitutions can then differentiate between
mechanisms of immune escape, exchange between A and
E at 180 was indicated to inﬂuence HI titres due to altered
antibody-epitope recognition rather than modulation of
receptor-binding avidity. Epitope mapping using mAbs
further indicated that residue 180 is a constituent of the
H9-A antigenic site.
We were able to detect a likely example of changing
immunodominance, demonstrating that such effects can
be distinguished using HI data. Substitutions between
aspartic acid and glycine at position 135 were observed to
impact titres measured using antisera raised to a D135
virus but not using antisera raised to a G135 virus. These
results suggest that an epitope involving position 135 is
immunodominant when a virus possesses D135 (aspartate
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Fig. 3 Heatmap showing the impacts of reciprocal amino-acid substitutions introduced at sites identiﬁed by modelling. Changes in HI titre
(log2) associated with each introduced substitution are shown by heatmap, measured using antiserum both lacking the introduced substitution
(parent-like) and possessing the introduced mutation (mutant-like) from combinations of the viruses UDL1/08, Em/R66 and HK/33982. Changes in HI
titre associated with each pair of substitutions were interpreted as effects of altered avidity and antigenicity using Equation 1, are also shown. Avidity
effects cause an increase (blue) or drop (orange) in titre depending on the direction of substitution while antigenic effects are the estimated change
in titre resulting from antigenic dissimilarity. X indicates not individually signiﬁcant
Fig. 4 Antigenic structure of H9 HA. Homotrimers of H9 HA. Selected receptor-binding residues shown in red (P92, G128, T129, S130, S131, A132,
W142, N173, L184, Y185, N214, G215, G218 and R219). Images made in Pymol52 (Schrödinger) based on the structure of A/swine/Hong Kong/9/1998
(Protein databank ID:1JSD)53. a Residues recognised by mouse mAbs, positions with updated site H9-A shown in green, H9-B residues shown in blue.
b Residues labelled with substitutions that affect the binding of chicken polyclonal antisera. Non-glycosylation altering substitutions shown in yellow;
glycosylation site adding mutations shown in black; site 150, which had both glycosylation adding and non-glycosylation adding mutations shown in
brown
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Table 3 Summary of residues investigated in this study and their relation to antigenicity and avidity
Position Antigenic 
site 
Amino 
acid 
diversitya 
Published 
mAb 
escapeb 
Identified by 
modellingc 
Impact on 
HId
Antigenic 
effecte 
Avidity 
effecte 
72 H9-B 1.92 G-E E-G-R G-E G-E - 
74  1.29 R-K R-G R-G 
98  1.00 L-Q - - 
109  2.37 S-R - - 
115 H9-B 1.03 Q-P, Q-R - Q-P 
120 H9-B 1.26 T-K - - 
121  1.06 - I-T I-T - I-T 
127 Overlap 2.72 S-N* - T-N* 
129 Site I 1.01 T-A, T-K - T-K
131  1.75 K-N* K-A/S, K-I, 
K-R, A-R  
K-I
135 H9-B/Site II 2.18 D-E, D-N D-G-N, D-E D-G D-G D-G 
137  1.00 F-L - F-L
139 H9-B 1.12 R-G, R-M - - 
145 H9-A 1.01 T-I - T-I
146 H9-A/Site I 2.02 Q-K - Q-H 
147  1.02 K-T - - 
148 Site I 1.65 N-D - N-D 
149 H9-A/Site I 2.12 N-D, N-K - G-D, G-K
150 Site I 3.93 A-T*, A-D A/N-V/L, A-
F, F-L, F-S-
T 
A-L, L-S* L-A, A-F L-A, A-
F 
152 Site I 1.00 P-L - - 
162 H9-B 2.37 R-W - - 
178 Site II 1.13 D-V - - 
179 H9-
A/Overlap 
1.06 T-A - T-N 
180 H9-A 3.45 - A-E-T, A-V, 
E-D 
A-E A-E A-E 
182 Site II 1.73 T-I - T-R 
183 H9-A/Site II 1.77 N-D, N-S, N-
T
N-D, N-E/T N-T N-T - 
188 Overlap 1.29 T-N* A-T T-N* 
189 Site II 1.01 D-N* - D-N* 
195  1.70 - A-T 
198  2.32 - D-N - 
212 H9-A 1.03 L-H, L-P - - 
216 Site II 1.49 L-Q L-Q L-Q L-Q L-Q 
217 H9-A 2.59 I-T I-Q, I-T I-L, I-M, I-
Q 
- I-L, I-Q 
234 H9-A 1.02 R-Q - - 
249  1.42 - I-V/A I-V - I-V 
264  1.85 - K-N 
276  1.41 - K-R 
288  1.44 - I-V 
306  1.02 - I-K
aInverse Simpson index, 1.00 equivalent to 100% conserved, numbers above 1.00 indicate increasing levels of diversity; bPublished mAb escape mutant, citations in
Table S1. cIdentiﬁed by integrated modelling of HI titres and gene sequence data (Table 2). dSigniﬁcant impact on HI titre as shown in Figs. 1 and/or 3. Estimated
impact of antigenicity and avidity change on HI titre if reciprocal mutations were analysed (Fig. 2). Substitutions associated with absent or almost absent (frequency <
1% among sequenced viruses) are shown in italicised font. Substitutions identiﬁed by mAb escape study or modelling but shown not to impact HI titres are indicated
by strikethrough. * Potential to add glycosylation site. Shaded cells indicate not tested
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has a prominent acidic side chain), but that antibody
responses generated against viruses possessing G135 are
directed to other regions (unsurprising, given that glycine
is the smallest amino acid). Substantial change in immu-
nodominance resulting from a single amino-acid sub-
stitution has previously been reported in human
inﬂuenza24. Although we did not detect any other cases of
asymmetric antigenic change, we speculate that the phe-
nomenon is perhaps widespread though hard to detect,
except in the most dramatic cases. Better understanding
of this phenomenon may facilitate the development of
vaccines designed to guide the immune response toward
more conserved epitopes providing better cross-
protection.
In contrast to previously validated applications of the
described modelling technique to human inﬂuenza A
(H1N1) and foot-and-mouth disease virus where very
large antigenic data sets ( > 10,000 titres) were collected
by a single laboratory under relatively consistent meth-
ods17,36, the data analysed here were drawn from multiple
sources and encompass varying experimental designs,
serum types and production methods. This is expected to
limit the accuracy of parameter coefﬁcient estimates and
potentially introduce false positives in terms of identiﬁed
residues (e.g., at position 140). Nonetheless, we identify
substitutions within previously deﬁned H9 antigenic sites
at new amino-acid positions and conﬁrm them experi-
mentally as antigenically important. This indicates that
such an approach can be extended to inﬂuenza subtypes
where multiple, smaller databases of antigenic data exist,
such as H5 and H7 viruses. Although this study used only
post infection chicken antisera for validation of antigenic
residues, it is possible that antibody response induced by
vaccination with inactivated, adjuvanted vaccine may
differ to some degree compared with those present post
infection.
In conclusion, we show that although mAb escape
mutant studies are undoubtedly helpful for understanding
virus antigenicity, escape mutations often have little or no
effect on inhibition by polyclonal antiserum drawn from
chickens, the target species of vaccination. In addition,
many escape mutants have not been found to emerge in
nature, perhaps owing to negative ﬁtness costs. Con-
versely, integrated modelling of sequence and HI data
directly provides information on the molecular basis of
antigenic variation speciﬁcally for circulating viruses, and
its conclusions can be easily validated by reverse genetics.
We anticipate that these results will contribute to future
vaccine development and seed strain assessment by pro-
viding quantitative molecular markers that can help
explain vaccine breakdown in the ﬁeld and predict levels
of antigenic drift during virus surveillance.
Materials and methods
Ethics statement
All described animal studies and procedures were car-
ried out in strict accordance with European and United
Kingdom Home Ofﬁce regulations and the Animals
(Scientiﬁc Procedures) Act 1986 Amendment Regula-
tions, 2012. These studies were carried out under the
United Kingdom Home Ofﬁce approved project license
numbers 30/2683 and 30/2952. In addition, the work had
undergone ethical scrutiny before approval by The Pirb-
right Institute’s Animal Welfare and Ethical Review Board
(AWERB).
Cells and eggs
MDCKs and HEK 293Ts (obtained from the European
Collection of Authenticated Cell Cultures) were grown in
Dulbecco modiﬁed Eagle media supplemented with 10%
fetal bovine serum at 37oC, 5% CO2. Virus was propagated
in 10-day-old embryonated chicken eggs (ValoBioMedia
GmbH), allantoic and amniotic ﬂuid was harvested and
pooled at 48 h post-inoculation.
Cloning and rescue of recombinant viruses
All viruses used in this study were generated through
reverse genetics as previously described25,37. Recombi-
nant, reassortant viruses were used for generation of
chicken antisera, whereby the HA of the named virus was
rescued with the remaining segments from A/chicken/
Pakistan/UDL-01/2008 (UDL1/08). For all other assays,
high growth reassortant 1:1:6 viruses were used where the
HA was taken from the named virus, the NA from UDL1/
08, and the remaining six internal genes from A/Puerto
Rico/8/1934 (PR8). Viruses with amino-acid substitutions
were generated through site directed mutagenesis. After
propagation, all viruses were Sanger sequenced in the
HA1 region to determine whether any reversions/com-
pensatory mutations had arisen, as previously described25.
Antisera production
Post infection chicken antisera were generated as
described previously38. In brief, 3-week-old speciﬁc
pathogen-free chickens were infected intranasally with
106 pfu of recombinant virus. Birds were monitored twice
daily for clinical signs. At 21 days post infection, birds
were killed and bled for antisera. All other antisera were
either purchased commercially or received as gifts from
collaborators.
Haemagglutination and HI assay
Haemagglutination and HI assays were performed as
described elsewhere39, using a solution of 1% chicken
red blood cells. All HI assays with mutant viruses were
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performed with a minimum of three technical repeats
with six individual chicken antisera. Linear mixed-
effects models were used to determine whether HI
titres recorded for mutant viruses were signiﬁcantly
different from those recorded for the parental virus.
Mutant viruses were considered in a combined model
with ﬁxed effects for each combination of parental virus
and for each introduced substitution. Random effects
were used to account for variation in titres attributable
to differences in antiserum drawn from different
chickens (biological repeats) and differences between
experiments (technical repeats).
Variation in HI titre associated with introduced sub-
stitutions resulting from changes in antigenicity and
avidity was estimated using a similar methodology to
previously described17. When reciprocal mutants were
tested (arbitrarily termed forward and reverse for the
purpose of explanation), both mutants were tested by HI
against antiserum to the parental virus lacking the for-
ward substitution (X) and antiserum to the parental virus
lacking the reverse substitution (Y). The impact of the
introduced substitution on antigenicity (d) and avidity (ν)
was estimated using:
HXXþ  NðHXX  d þ v; σ2Þ
HYXþ  NðHYX þ kd þ v; σ2Þ
HYY  NðHYY  d  v; σ2Þ
HXY  NðHXY þ kd  v; σ2Þ
ð1Þ
where titres for each mutant virus are assumed to be
normally distributed (N()) with a mean depending on
titres recorded for the parental virus and the antigenic and
avidity effects of the introduced substitution and variance
σ2. HYX is the log2 titre for the virus X tested with anti-
serum raised against the virus Y, and X+ and Y− are the
reciprocal mutant viruses possessing forward and reverse
substitutions, respectively. Thus, HXY− is the log2 titre for
the mutant virus Y− and antiserum raised against the
virus X. The full antigenic effect of an introduced sub-
stitution is apparent when measured using parental anti-
serum, but that effect may be obscured to some degree
when measured using an antiserum raised against a dis-
tinct virus owing to other antigenic differences. k is the
proportion of the full antigenic impact of a substitution
that is observed (i.e., not obscured) using antiserum raised
against a distinct virus. To investigate a potential asym-
metric antigenic effect, an alternative model that allowed
d on lines one and four of Equation 1 to differ from d on
lines two and three was used. Parameters in the above
equations were co-estimated in a Bayesian model with
minimally informative priors using JAGS v3.3.0 via the
runjags R package v2.0.3.240,41.
Receptor-destroying enzyme-based avidity assay
Solutions of 1% chicken red blood cells were treated
with differing concentrations (8–1024 ng/ml) of a
receptor-destroying enzyme (RDE; neuraminidase from
Vibrio cholerae, type II, Sigma-Aldrich cat no. N6514) for
1 h at 37oC. Red blood cells were then washed twice and
resuspended in phosphate buffered saline. In total, 50 µl of
RDE treated blood was added to four hemagglutinating
unit of viruses and put on ice. Plates were read after 1 h,
the highest concentration of RDE that still allowed com-
plete haemagglutination was recorded as the relative
avidity.
Western blotting of glycosylation mutant viruses
Allantoic ﬂuid containing glycosylation mutants was
concentrated by ultracentrifugation at 27,000 rpm for 2 h.
Concentrated viruses were then run on 7.5% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
western blotted. A cocktail of anti-UDL1/08 mAbs, the
previously described JF7, IB3, ID2 and IG1025, were used
to probe HA1, a band shift was then used to determine
presence or absence of glycosylation sites.
Genetic and antigenic data
HI data were collated from a combination of published
literature, WHO candidate vaccine virus reports, publicly
available theses and previously unpublished data from our
laboratory (Table S4 and S5). All available H9N2 HA
sequences were downloaded from the NCBI inﬂuenza
database (https://www.ncbi.nlm.nih.gov/genomes/FLU/
Database/nph-select.cgi?go= database) or the GISAID
EpiFlu database (http://platform.gisaid.org). The HI data
set (see data availability statement) matched to sequence
data comprised 2547 individual titre measurements
between 328 test viruses and antisera raised against 103
viruses. In total 2131 virus-antisera combinations were
represented in the data set. The data set included antisera
drawn from various species and included both post
infection and post vaccination (hyperimmune) antisera.
868 titres were measured using chicken hyperimmune
antisera, 836 using chicken post infection, 796 using ferret
post infection, 60 using rabbit hyperimmune, seven sheep
hyperimmune and seven goat hyperimmune.
Phylogenetic analysis
Time-resolved phylogenetic trees were reconstructed
from HA1-nucleotide sequences using a variety of models
of sequence evolution implemented using BEAST v1.8.242
and tested through comparison of Bayes factors43. The
general time reversible model with a proportion of
invariant sites and a gamma distribution describing
among-site rate variation with four categories estimated
from the data (GTR+ I+ Γ4) was identiﬁed as the best
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model of nucleotide substitution. Bayes factor analysis
also determined that a codon-position model allowing
rates of nucleotide substitution to vary at the third codon
position, a relaxed molecular clock with branch rates
drawn from a lognormal distribution44, and a minimally
constrained Bayesian skyline demographic model should
be used45. The maximum clade credibility tree was
visualised alongside amino-acid alignments using the
ggtree package46.
Statistical modelling and model selection
Substitutions responsible for changes in antigenic
phenotype during the evolution of the virus were pre-
dicted using a modelling approach adapted from that
previously described17. The geometric (log2) HI titre was
used as the response variable throughout. Mixed models
constructed using the lme4 package47 and R v3.3.048,
including each of the following variables were assessed
by likelihood ratio test: the test virus, the reference virus
against which the antiserum was raised, the type of
antisera used which encompasses species inoculated and
method of inoculation (i.e., post infection or post vac-
cination), and the study from which data were collected.
To prevent false support for substitutions owing to
repeated measurements that arise owing to the evolu-
tionary relationships between viruses, phylogenetic
information was included in the model. Phylogeny
branches associated with antigenicity changing events
were identiﬁed as previously described17,36,49. In addi-
tion, phylogenetic terms associated with changes in
receptor-binding avidity and immunogenicity were
identiﬁed. These branches led to clades of viruses/
antisera that tended to have higher or lower titres,
notwithstanding antigenic relationships. Owing to the
size of the search space, the optimal combination of
these various binary variables reﬂecting phylogenetic
structure was determined using random restart hill-
climbing as previously described17,50.
To investigate the effect of amino-acid substitutions at
speciﬁc positions, amino-acid dissimilarity between the
reference virus and test virus at each variable HA1 posi-
tion was tested as a predictor of reduced HI titre (p <
0.05), both before and after correcting for multiple test-
ing51. Positions were tested alongside phylogenetic terms,
therefore substitution at an identiﬁed position must cor-
relate with variation in titre in independent branches of
the phylogeny: i.e., there are convergent, alternative, or
back-substitutions associated with reduced cross-
reactivity. To identify antigenically distinct amino acids
at identiﬁed positions, the binary term indicating pre-
sence, or absence, of substitution was replaced with a
variable with levels for every pair of amino acids observed
between two viruses tested together by HI. Estimates of
the antigenic impact of substitutions were made by
examining associated regression coefﬁcients for substitu-
tion terms included in combination in the absence of
phylogenetic terms.
Diversity
Diversity across different amino-acid positions was
calculated using Inverse Simpson index using all 2523 full
length H9 HA sequences downloaded from the NCBI
inﬂuenza database (https://www.ncbi.nlm.nih.gov/
genomes/FLU/Database/nph-select.cgi?go= database) as
of July 2017.
Data availability statement
References for HI data collated from a combination of
published literature, WHO candidate vaccine virus
reports and publicly available theses are detailed in
Table S4. Additional novel HI data to supplement these
are included in Table S5. All available H9N2 HA
sequences were downloaded from the publicly accessible
NCBI inﬂuenza database (https://www.ncbi.nlm.nih.gov/
genomes/FLU/Database/nph-select.cgi?go= database)
and the GISAID EpiFlu database (http://platform.gisaid.
org).
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